159 related articles for article (PubMed ID: 30965212)
1. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?
Bayle A; Besse B; Annereau M; Bonastre J
Eur J Cancer; 2019 May; 113():28-31. PubMed ID: 30965212
[TBL] [Abstract][Full Text] [Related]
2. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.
Hall E; Zhang J; Kim EJ; Hwang G; Chu G; Bhatia S; Reddy S
Cancer Med; 2020 Mar; 9(6):2106-2112. PubMed ID: 31994335
[TBL] [Abstract][Full Text] [Related]
3. A real-world data approach to determine the optimal dosing strategy for pembrolizumab.
Jang A; Nakashima L; Ng T; Fung M; Jiwani S; Schaff K; Suess J; Goncalves R; Jang D; Kuik K; Labelle S; Pow A
J Oncol Pharm Pract; 2021 Apr; 27(3):635-643. PubMed ID: 32539663
[TBL] [Abstract][Full Text] [Related]
4. Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study.
Mukherjee S; Ibrahimi S; Machiorlatti M; Roman D; Saleem R; Hassan A; Baxley A; Vesely S; Aljumaily R
Am J Ther; 2018; 25(6):e767-e768. PubMed ID: 29746291
[No Abstract] [Full Text] [Related]
5. A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.
Goldstein DA; Gordon N; Davidescu M; Leshno M; Steuer CE; Patel N; Stemmer SM; Zer A
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059432
[TBL] [Abstract][Full Text] [Related]
6. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.
Tartari F; Santoni M; Burattini L; Mazzanti P; Onofri A; Berardi R
Cancer Treat Rev; 2016 Jul; 48():20-4. PubMed ID: 27310708
[TBL] [Abstract][Full Text] [Related]
7. Medication use evaluation of programmed death-1 inhibitors in a veteran population.
Nguyen V; Huq M
J Oncol Pharm Pract; 2019 Jul; 25(5):1066-1075. PubMed ID: 29726785
[TBL] [Abstract][Full Text] [Related]
8. Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis.
Ogungbenro K; Patel A; Duncombe R; Nuttall R; Clark J; Lorigan P
Clin Pharmacol Ther; 2018 Apr; 103(4):582-590. PubMed ID: 28913853
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
10. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
Criss SD; Weaver DT; Sheehan DF; Lee RJ; Pandharipande PV; Kong CY
Urol Oncol; 2019 Mar; 37(3):180.e11-180.e18. PubMed ID: 30528699
[TBL] [Abstract][Full Text] [Related]
11. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
Choi B; McBride A; Scott AJ
Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
13. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.
Kilickap S; Guven DC; Aktepe OH; Aktas BY; Dizdar O
J Oncol Pharm Pract; 2020 Mar; 26(2):496-499. PubMed ID: 31256744
[TBL] [Abstract][Full Text] [Related]
14. Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma.
Mennini FS; Bini C; Marcellusi A; Del Vecchio M
Clin Drug Investig; 2018 Oct; 38(10):967-976. PubMed ID: 30143953
[TBL] [Abstract][Full Text] [Related]
15. Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma.
Ohashi H; Takeuchi S; Miyagaki T; Kadono T
Drug Discov Ther; 2020 Jul; 14(3):117-121. PubMed ID: 32595179
[TBL] [Abstract][Full Text] [Related]
16. Follow up survey for implementation of fixed-dosing of monoclonal antibodies.
Heinhuis KM; Beijnen JH; Hendrikx JJMA
Int J Clin Pharm; 2020 Feb; 42(1):3-6. PubMed ID: 32026351
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
Ahn BC; Pyo KH; Xin CF; Jung D; Shim HS; Lee CY; Park SY; Yoon HI; Hong MH; Cho BC; Kim HR
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1613-1623. PubMed ID: 30911841
[TBL] [Abstract][Full Text] [Related]
18. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
20. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
